Replies to post #135640 on Biotech Values

[ciotera]

re: GILD strategy

It's less of an approval hedge and more of a lock on all best-in-class third agent combinations (NNRTI, PI, II) - makes sense to convert all of these to fixed dose combo before Truvada goes generic.